Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 4/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | GBA1 | P04062 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LCT | P09848 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | AGL | P35573 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2267141 | 0.86 | MGAM (0.46) | MGAMFUCA1GAAGBA1 | |
| SCHEMBL2273447 | 0.83 | MGAM (0.69) | MGAMGAAGBA1SIAGL | |
| SCHEMBL4106580 | 0.82 | MGAM (0.58) | MGAMFUCA1GAAGBA1TDP1 | |
| SCHEMBL13848042 | 0.82 | MGAM (0.58) | MGAMFUCA1GAAGBA1TDP1 | |
| SCHEMBL14624581 | 0.82 | MGAM (0.58) | MGAMFUCA1GAAGBA1TDP1 | |
| SCHEMBL14624899 | 0.82 | MGAM (0.58) | MGAMFUCA1GAAGBA1TDP1 | |
| SCHEMBL13004948 | 0.82 | MGAM (0.58) | MGAMFUCA1GAAGBA1TDP1 | |
| SCHEMBL2438771 | 0.82 | MGAM (0.58) | MGAMFUCA1GAAGBA1TDP1 | |
| SCHEMBL2270084 | 0.80 | MGAM (0.60) | MGAMGAAGBA1 | |
| SCHEMBL12497891 | 0.80 | MGAM (0.60) | MGAMGAAGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | MGAM 36/4885FUCA1 17/4885GAA 1/4885 |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | GPI, GALE, HAVCR2 | MGAM 43/4885FUCA1 83/4885GAA 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.